KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Purchased by Suvretta Capital Management LLC

Suvretta Capital Management LLC grew its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 0.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,212,005 shares of the specialty pharmaceutical company’s stock after acquiring an additional 20,000 shares during the quarter. KalVista Pharmaceuticals comprises about 1.6% of Suvretta Capital Management LLC’s investment portfolio, making the stock its 23rd largest holding. Suvretta Capital Management LLC owned about 9.75% of KalVista Pharmaceuticals worth $48,775,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of KALV. PEAK6 Investments LLC bought a new stake in KalVista Pharmaceuticals in the 1st quarter valued at about $178,000. Price T Rowe Associates Inc. MD increased its stake in shares of KalVista Pharmaceuticals by 4.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 22,142 shares of the specialty pharmaceutical company’s stock valued at $263,000 after purchasing an additional 944 shares during the period. Rosalind Advisors Inc. raised its holdings in shares of KalVista Pharmaceuticals by 17.4% during the second quarter. Rosalind Advisors Inc. now owns 337,985 shares of the specialty pharmaceutical company’s stock valued at $3,981,000 after buying an additional 50,000 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of KalVista Pharmaceuticals by 21.0% during the second quarter. Bank of New York Mellon Corp now owns 135,600 shares of the specialty pharmaceutical company’s stock worth $1,597,000 after buying an additional 23,547 shares during the period. Finally, nVerses Capital LLC bought a new position in KalVista Pharmaceuticals in the 2nd quarter worth approximately $25,000.

Analysts Set New Price Targets

Several analysts have weighed in on KALV shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, September 9th. Needham & Company LLC reissued a “buy” rating and set a $32.00 price target on shares of KalVista Pharmaceuticals in a report on Friday, September 6th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a report on Monday, October 7th.

Insiders Place Their Bets

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 14,400 shares of the company’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $9.26, for a total value of $133,344.00. Following the transaction, the chief executive officer now owns 266,598 shares of the company’s stock, valued at approximately $2,468,697.48. This represents a 5.12 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Paul K. Audhya sold 8,077 shares of the stock in a transaction on Monday, November 18th. The shares were sold at an average price of $9.26, for a total value of $74,793.02. Following the sale, the insider now owns 94,199 shares of the company’s stock, valued at $872,282.74. This trade represents a 7.90 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 32,016 shares of company stock worth $319,344. 10.50% of the stock is owned by corporate insiders.

KalVista Pharmaceuticals Price Performance

NASDAQ KALV opened at $10.09 on Friday. KalVista Pharmaceuticals, Inc. has a 12 month low of $7.39 and a 12 month high of $16.88. The firm has a market capitalization of $436.09 million, a PE ratio of -2.86 and a beta of 0.92. The company’s 50 day simple moving average is $10.98 and its 200 day simple moving average is $11.93.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.91) by $0.04. Sell-side analysts anticipate that KalVista Pharmaceuticals, Inc. will post -2.7 earnings per share for the current fiscal year.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).